Stockreport

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation fro [Read more]